Factors Associated with Positive F-18 Flurodeoxyglucose Positron Emission Tomography Before Thyroidectomy in Patients with Papillary Thyroid Carcinoma
Kim BS et al. – Pre-thyroidectomy (pre-Tx) F-18 flurodeoxyglucose (FDG) positron emission tomography (PET) is not recommended for routine use in patients with papillary thyroid carcinoma (PTC).
Patients were selected for a retrospective review of their records if they had a total Tx with central lymph node dissection for PTC and pre-Tx FDG PET-CT and US between 2006 and 2009.
Sixty patients who met these criteria were studied.
Patients who had a history of head and neck irradiation, surgery, or sclerotherapy with ethanol in the last 3 months were excluded.
The clinicopathologic factors-age, sex, size, tumor-node-metastasis (TNM) staging, the presence of extrathyroidal extention, multifocality, cervical lymph node metastases (CLNM), Hashimoto thyroiditis, and US characteristics-were evaluated to determine whether they were associated with positive pre-Tx FDG uptake.
Forty-three (71.6%) of patients in the study had positive FDG uptake.
Larger tumors and the presence of CLNM were associated with a greater likelihood of positive FDG uptake.
The sensitivity, specificity, positive predictive value, and negative predictive value for CLNM detection by FDG PET-CT showed low statistical values.
When considering the excellence of US for evaluating a thyroid nodule size and the presence of CLNM, the clinical value of pre-Tx FDG PET-CT is comparatively limited.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.